Stomach (Gastric) Cancer Prevention (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (05/27/2016)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Description of the Evidence

Added text about a systematic review and meta-analysis of randomized control trials and observational studies that was done to assess the treatment of Helicobacter pylori with curative regimens for three different clinical scenarios: asymptomatic patients, patients with atrophic gastritis and intestinal metaplasia, and patients who have had endoscopic treatment for cancer (cited Lee et al. as reference 20).

Added text to state that the authors found 24 eligible studies with 715 incidences of gastric cancer among 48,000 individuals in 340,000 person-years of follow-up; individuals with eradication treatment for H. pylori had a lower incidence of gastric cancer, and treatment was associated with substantially lower risk in individuals who had asymptomatic infection and in individuals after endoscopic resection of gastric cancer. Also added text to state that the results may have implications for the treatment of some subgroups of individuals with particularly high risk, such as Asian immigrant populations in the United States and individuals with underlying gastric mucosal disease; or to help prevent recurrent gastric cancer.

This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Description of the Evidence

Next section >
About This PDQ Summary